Drugs / OTX-2002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05497453 | Aug 2022 → Nov 2024 | hepatocellular carcinoma | Omega Therapeutics | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OTX-2002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05497453 ↗ |
| Modality | Messenger RNA (mRNA) | “contains a biscistronic mRNA” NCT05497453 ↗ |
| Route | Intravenous | “OTX-2002 will be administered as an IV infusion over 80-120 minutes every 2 weeks” NCT05497453 ↗ |